Valine alpha-hydroxyisocaproate

Synopsis

Valine Alpha-Hydroxyisocaproate

1. Identity, Nomenclature, and Chemical Nature

The term valine alpha-hydroxyisocaproate refers to a compound or formulation situated at the intersection of two branched-chain amino acid (BCAA) metabolite families. To understand it fully, both of its constituent parts must be characterized precisely.

1.1 Alpha-Hydroxyisocaproic Acid (HICA)

DL-α-hydroxyisocaproic acid (HICA), also known as leucic acid or DL-2-hydroxy-4-methylvaleric acid, is an end product of leucine metabolism in human tissues such as muscle and connective tissue. The compound's systematic IUPAC name is 2-hydroxy-4-methylpentanoic acid, and it belongs to the broader class of alpha-hydroxy carboxylic acids. Alpha hydroxy carboxylic acids, or α-hydroxy carboxylic acids (AHAs), are a group of carboxylic acids featuring a hydroxy group located one carbon atom away from the acid group.

In the NLM MeSH Browser, alpha-hydroxyisocaproic acid carries CAS registry number 498-36-2 (without isomeric designation) and is classified as the alpha-hydroxy analog of leucine. Known entry terms include 2-hydroxyisocaproic acid, and it exists as distinct (R)- and (S)-isomers, as well as calcium and monosodium salt forms.

1.2 Valine and Its Alpha-Hydroxy Analog

Valine (symbol Val or V) is an α-amino acid that is used in the biosynthesis of proteins. It is one of the three branched-chain amino acids, alongside leucine and isoleucine. The corresponding alpha-hydroxy metabolite of valine is alpha-hydroxyisovaleric acid (HIVA), also known as 2-hydroxy-3-methylbutanoic acid.

2-Hydroxy-3-methylbutanoic acid (α-Hydroxyisovaleric acid) is an α-hydroxy analogue of valine and a valine precursor that reduces urea excretion. It can promote the growth of chickens and rats, and is converted into valine in the body, participating in protein synthesis and maintaining nitrogen balance, thereby supporting animal growth and development.

1.3 "Valine Alpha-Hydroxyisocaproate" as a Compound Designation

In the dietary supplement and patent literature, the phrase "valine alpha-hydroxyisocaproate" is used to describe formulations or salt complexes in which the amino acid valine is combined with alpha-hydroxyisocaproate (the conjugate base/salt of HICA). This usage parallels the naming convention of other amino acid-mineral or amino acid-acid salt complexes (e.g., calcium alpha-hydroxyisocaproate). In additional aspects of related patents, α-hydroxyisocaproic acid (HICA) may be replaced by other α-hydroxy branched-chain amino acid metabolites, such as α-hydroxy-β-methylvaleric acid (HIMVA) and α-hydroxy-isovaleric acid (HIVA). This indicates that the alpha-hydroxyisocaproate anion is understood within a broader family of structurally related BCAA-derived hydroxy acids, of which valine produces HIVA as its corresponding member.

For clarity, the present article addresses the science of the full alpha-hydroxy BCAA family — particularly HICA (the most studied member) and HIVA (valine's direct analog) — as these are the biochemically distinct entities underlying any product designated "valine alpha-hydroxyisocaproate."

1.4 Common Forms and Preparations

HICA is commercially available in several forms. In clinical studies, the sodium salt of HICA (583 mg, corresponding to 500 mg of free HICA) was used as the active ingredient mixed with liquid. HICA calcium refers to α-Hydroxyisocaproic Acid bound to a calcium salt. Supplement manufacturers often bind organic acids like HICA to minerals like calcium to improve the compound's stability, shelf life, and solubility in water. The free acid form (leucic acid/DL-2-hydroxy-4-methylvaleric acid) also exists as a white crystalline powder. This compound is typically a white crystalline solid and is soluble in water, which enhances its bioavailability.

2. Natural Sources

Both HICA and HIVA are normal constituents of human metabolism and of certain fermented foods, arising endogenously from BCAA catabolism.

2.1 Endogenous Production

2-hydroxyisocaproic acid (HICA) is a natural compound produced through the leucine degradation pathway and is produced in humans and by certain microorganisms such as lactic acid bacteria and Clostridium species. The parallel valine-derived metabolite, HIVA, is likewise an endogenous compound arising from valine catabolism, and its measurement in plasma has been documented in normal human volunteers. Plasma concentrations of leucine's and isoleucine's transamination products alpha-ketoisocaproic acid (KICA) and alpha-keto-beta-methylvaleric acid (KMVA) are known to increase after a protein meal or during extended fasting, but little or no increase in the concentration of valine's transamination product, alpha-ketoisovaleric acid (KIVA), has been observed under these conditions. To determine whether this could be explained by the conversion of KIVA to its alpha-hydroxy analogue, researchers measured the plasma concentrations of KICA, KMVA and KIVA, as well as their alpha-hydroxy analogues [alpha-hydroxyisocaproic acid (HICA), alpha-hydroxy-beta-methylvaleric acid (HMVA) and alpha-hydroxyisovaleric acid (HIVA)], in normal volunteers immediately after a protein meal or during a 60-h fast.

2.2 Fermented Food Sources

DL-α-hydroxy-isocaproic acid (HICA), also known as leucic acid or DL-2-hydroxy-4-methylvaleric acid, is an end product of leucine metabolism in human tissues such as muscle and connective tissue. Some foodstuffs produced by fermentation, e.g. certain cheeses, wines and soy sauce contain HICA. Kimchi has also been identified as a source: a 2017 paper published in Scientific Reports documented the identification of HICA production by lactic acid bacteria and evaluated microbial dynamics during kimchi ripening.

3. Traditional and Historical Use

HICA and HIVA as isolated compounds have no documented history of traditional or ethnobotanical use in any medical or cultural tradition. They are not derived from plant sources and were not identified as distinct chemical entities until mid-to-late-twentieth-century biochemical research. Their characterization as metabolic intermediates of BCAA catabolism emerged from laboratory investigations rather than from folk or traditional medicine.

The parent amino acid valine, along with leucine and isoleucine, is a fundamental component of dietary protein, which has of course been consumed throughout human history in protein-containing foods (meat, legumes, dairy). However, the specific isolation or intentional use of alpha-hydroxy BCAA metabolites as supplements is a product of modern sports nutrition science, originating largely from the late 1970s onward when researchers began investigating nitrogen-free amino acid analogs as potential therapeutics for chronic renal failure and protein metabolism disorders. A 1978 U.S. patent described therapeutic compositions comprising alpha-hydroxy analogs of essential amino acids and their administration to humans for promotion of protein synthesis and suppression of urea formation.

4. Key Constituents and Mechanisms of Action

4.1 Biochemical Origin: The BCAA Metabolic Pathway

α-Ketoisocaproic acid (α-KIC), also known as 4-methyl-2-oxovaleric acid, and its conjugate base and carboxylate, α-ketoisocaproate, are metabolic intermediates in the metabolic pathway for L-leucine. α-KIC is produced in one of the first steps of the pathway by branched-chain amino acid aminotransferase by transferring the amine on L-leucine onto alpha ketoglutarate, and replacing that amine with a ketone. HICA is subsequently generated from α-KIC by the action of hydroxy acid dehydrogenases. The metabolism of leucine follows two potential pathways — toward HMB or KIC — the latter eventually converting into HICA.

Alfa-Hydroxy-isocaproic acid (HICA) is an end product of leucine metabolism in human tissues such as muscle and connective tissue. The analogous valine pathway produces alpha-ketoisovaleric acid (KIVA), which can in turn be reduced to HIVA (alpha-hydroxyisovaleric acid). Research in human volunteers has demonstrated that — unlike the keto acids of leucine and isoleucine — plasma KIVA levels do not markedly rise after a protein meal or fasting, which led investigators to hypothesize enhanced conversion of KIVA to its hydroxy form HIVA.

4.2 Anti-Catabolic Mechanisms

According to clinical and experimental studies, HICA can be considered as an anti-catabolic substance. There is evidence of a direct in vitro inhibitory effect of HICA on various matrix metalloproteinase enzymes, which are responsible for degradation of various connective and protein tissues. Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade extracellular matrix components; their inhibition may reduce the proteolytic breakdown associated with intense exercise, injury, and disuse atrophy.

According to clinical and experimental studies, HICA can be considered as an anticatabolic substance that may also increase muscle protein synthesis in some situations. Although leucine has a unique role as a promoter of protein synthesis, metabolites of leucine may be more effective in preventing breakdown of proteins, particularly muscle proteins.

4.3 Protein Synthesis and mTOR Signaling

Data from animal studies suggest that whereas α-HICA does not slow the loss of muscle produced by disuse, it does speed recovery at least in part by maintaining an increased rate of protein synthesis. The mammalian target of rapamycin (mTOR) signaling cascade — the same pathway activated by leucine — has been implicated in HICA's anabolic effects, though the precise binding or upstream receptor for HICA within this pathway has not been definitively established in human mechanistic studies.

4.4 Antimicrobial Properties

Studies have investigated the antibacterial efficacy of HICA against important bacteria associated with food quality and safety. The results revealed that HICA was effective in inhibiting the growth of tested Gram-positive and Gram-negative bacteria including a multi-drug resistant P. aeruginosa strain. The underlying mechanism was investigated by measuring the cell membrane integrity, membrane permeability, membrane depolarisation, and morphological and ultrastructural changes after HICA treatment in bacterial cells. The ability of HICA to permeabilise the outer membrane, even at concentrations lower than its MIC, makes it a permeabiliser lacking inherent toxicity at that particular concentration, but which could sensitise bacteria to other antimicrobial agents when used in combination.

4.5 HIVA as a Valine-Derived Alpha-Hydroxy Acid

2-Hydroxy-3-methylbutanoic acid (α-Hydroxyisovaleric acid) is an α-hydroxy analogue of valine and a valine precursor that reduces urea excretion. It can promote growth and is converted into valine in the body, participating in protein synthesis and maintaining nitrogen balance. Animal studies have confirmed that HIVA possesses growth-promoting activity via its conversion back to valine, providing an alternate nitrogen source. 2-Hydroxy-3-methylbutanoic acid has a more significant effect in the valine-deficient dietary model.

Early comparative research in animal models quantified the relative efficacy of valine and its analogs. The isomers of valine and alpha-hydroxyisovaleric acid had efficacy values in chicks of: DL-Val, 84%; D-Val, 72%; L-HIV, 82%; DL-HIV, 79%; D-HIV, 66%. D-Val had only marginal growth-promoting activity for rats, 16%. All Val analogs had comparable efficacy values for the rat: alpha-ketoisovaleric acid (KIV), 49%; L-HIV, 54%; DL-HIV, 51%; and D-HIV, 46%. These findings were interpreted as suggesting that the BCAA keto analogs were not superior to the L-alpha-hydroxy analogs in growth-promoting capacity, and this is of great interest for the potential use of these nitrogen-free amino acid analogs in nutritional therapy.

5. Scientific Evidence by Area of Use

5.1 Skeletal Muscle Mass and Body Composition

Human Clinical Evidence

The most cited human study on HICA supplementation was a randomized, double-blind, placebo-controlled trial in athletes. The study investigated the effects of HICA supplementation on body composition, delayed onset of muscle soreness (DOMS) and physical performance of athletes during a training period. Fifteen healthy male soccer players (age 22.1 ± 3.9 yr) volunteered for the 4-week double-blind study during an intensive training period. Subjects in the HICA group (n = 8) received 583 mg of sodium salt of HICA (corresponding to 500 mg of HICA) mixed with liquid three times a day for 4 weeks, and those in the placebo group (n = 7) received 650 mg of maltodextrin mixed with liquid three times a day for the same period. Body composition was assessed by dual-energy X-ray absorptiometry (DXA). A 4-week supplementation period with HICA (1.5 g daily) increased whole-body lean mass in soccer players. Their average protein intake was already rather high, 1.6–1.7 g/kg/day, and the intake of HICA per day was 1.5 g. It was concluded that ingestion of this extra "amino acid" HICA, even with sufficient daily protein and thus probably also leucine intake, increases lean muscle mass.

However, this finding has not been consistently replicated in subsequent, larger trials. A 2019 randomized controlled trial published in Medicine & Science in Sports & Exercise (Teixeira et al.) enrolled forty men in a double-blind protocol. β-hydroxy-β-methylbutyrate (HMB-Ca and HMB-FA) and α-hydroxyisocaproic acid (α-HICA) are leucine metabolites that have been proposed to improve body composition and strength when combined with resistance exercise training (RET). In this double-blind randomized controlled pragmatic trial, the effects of off-the-shelf supplements — α-HICA, HMB-FA and HMB-Ca — on RET-induced changes in body composition and performance were evaluated. Forty men were blocked randomized to receive α-HICA (n = 10), HMB-FA (n = 11), HMB-Ca (n = 9), or placebo (PLA; n = 10). The training protocol consisted of a whole-body resistance training routine, thrice weekly for 8 weeks. No statistically significant between-group or group-by-time interactions were observed. Supplementation with HMB (FA and Ca) or α-HICA failed to enhance body composition to a greater extent than placebo. The authors concluded they do not recommend these leucine metabolites for improving body composition changes with RET in young adult resistance trained men.

A parallel trial published in the European Journal of Sport Science (also Teixeira et al., 2019) yielded essentially the same findings: Supplementation with HMB (FA and Ca) or α-HICA failed to enhance body composition to a greater extent than placebo. The authors do not recommend these leucine metabolites for improving body composition changes with RET in young adult resistance trained men.

A third trial from the same research group, published in the Journal of Sports Sciences in 2019, examined inflammatory markers: No leucine metabolite attenuated inflammation during training. Additionally, backwards elimination regressions showed that no circulating inflammatory marker consistently shared variance with the change in any outcome.

Evidence strength assessment: Evidence for HICA's ability to increase lean mass is weak and inconsistent. The sole positive human study (Karila et al., 2009) involved only 15 subjects, a 4-week duration, and had notable conflicts of interest — the authors Dr. Tuomo Karila and Dr. Timo Seppälä are inventors of the HICA patent and also partners at Oy Elmomed Ltd. Subsequent, larger, better-powered trials have failed to replicate the finding. The body of evidence, taken as a whole, does not support a robust anabolic effect of HICA supplementation in resistance-trained men.

Animal Evidence

A rat study addressed the hypothesis that a diet containing 5% α-hydroxyisocaproic acid (α-HICA), a leucine metabolite, would slow the loss and/or improve recovery of muscle mass in response to disuse. Adult 14-wk-old male Wistar rats were provided a control diet or an isonitrogenous isocaloric diet containing either 5% α-HICA or leucine. Disuse atrophy was produced by unilateral hindlimb immobilization ("casting") for 7 days. Neither HICA nor Leu supplementation were able to prevent muscle atrophy, but after 14 days of recovery, only the HICA group demonstrated a return to normal muscle mass, and this correlated with a continuous increase in protein synthesis. These findings are preliminary and limited in their translatability to humans.

5.2 Delayed Onset Muscle Soreness (DOMS)

Reducing exercise-induced muscle soreness is the area where HICA has garnered the most consistent early interest. The most important finding of the pilot study was, however, that subjects when using HICA did not suffer from DOMS symptoms at all, or they suffered markedly less than before the treatment with HICA. In the 4-week soccer player trial, HICA supplementation of 1.5 g a day leads to small increases in muscle mass during a four week intensive training period in soccer athletes, and DOMS reduction was a co-primary outcome that reached significance.

Mechanistic explanations for anti-DOMS effects remain speculative. The mechanism by which HICA alleviates DOMS symptoms is unclear. The proposed link to MMP inhibition (reducing connective tissue proteolysis) is supported only by in vitro data. Several studies indicate that free branched-chain amino acids (BCAAs), especially leucine, and their transaminated metabolites, such as alpha-ketoisocaproic acid (KIC), may alleviate symptoms associated with exercise-induced catabolism. However, the 2019 inflammatory marker study found no reduction in markers such as creatine kinase, IL-6, or hsCRP from HICA supplementation, which casts further doubt on an anti-inflammatory mechanism in humans.

Evidence strength assessment: Preliminary and based on a single small study with significant conflicts of interest. Larger trials did not confirm reduced inflammation. The DOMS reduction claim requires independent replication.

5.3 Athletic Performance

Both the Karila et al. (2009/2010) trial and the Teixeira et al. (2018/2019) trials included measures of athletic performance (sprinting, jumping, strength). No leucine metabolite resulted in any ergogenic effects on any outcome variable. Supplementation with leucine metabolites — α-HICA, HMB-FA, or HMB-CA — is not a supplementation strategy that improves muscle growth and strength development in young adult men.

Evidence strength assessment: The weight of evidence from adequately powered randomized controlled trials finds no ergogenic benefit from HICA supplementation on strength, power, or muscular performance outcomes.

5.4 Antimicrobial Applications

HICA has been studied for antimicrobial properties in both food science and clinical (dental/endodontic) contexts. HICA has previously shown antimicrobial activity against clinically important bacteria and fungi. Its potential application in food preservation through inhibiting the growth of food spoilage and food-borne pathogenic bacteria has been investigated. It has been suggested that HICA could be used as a novel and safe antimicrobial compound in food preservation, as it is a natural compound in food products and is metabolized by the human body.

Studies also explored HICA in regenerative endodontics. One study assessed the effect of 2-hydroxyisocaproic acid (HICA) on the TGF-β1, IGF-1, BMP-7, and VEGF-A release from root canal dentin, compared to calcium hydroxide and double antibiotic paste in regenerative endodontic treatments. Forty-eight single-canal teeth were prepared to mimic immature teeth and treated according to the RET protocol. Teeth were divided into three experimental (HICA, CH, and DAP) and one control group. TGF-β1, BMP-7, IGF-1 and VEGF-A levels were measured using an ELISA kit on days 1 and 7.

Evidence strength assessment: Antimicrobial data for HICA are primarily in vitro and ex vivo. No clinical trials in humans have tested HICA as a therapeutic antimicrobial agent or food preservative. This is a nascent research area.

5.5 Muscle Atrophy, Disuse, and Disease States

Muscle disuse atrophy is observed routinely in patients recovering from traumatic injury and can be either generalized resulting from extended bed rest or localized resulting from single-limb immobilization. The rat immobilization model described above provides the primary pre-clinical rationale for HICA's potential role in atrophy prevention and recovery.

A case study published in the Yale Journal of Biology and Medicine (referenced in Teixeira et al., 2019) explored HICA's effects in a Type I diabetic patient with muscle atrophy, representing the only reported clinical use in a disease context. However, a single case study cannot establish efficacy and is not sufficient to draw clinical conclusions.

For valine specifically, research has shown that dietary valine is essential for hematopoietic stem cell (HSC) self-renewal, as demonstrated by experiments in mice. Dietary valine restriction selectively depletes long-term repopulating HSC in mouse bone marrow. These findings relate to the intact amino acid valine rather than to its alpha-hydroxy metabolite.

5.6 Metabolic and Insulin Sensitivity Effects

Research on the valine catabolism product 3-hydroxyisobutyrate (3-HIB, a distinct metabolite separate from HIVA) has revealed effects on lipid metabolism. The valine catabolite 3-hydroxyisobutyrate promotes insulin resistance in mice by stimulating fatty acid uptake into muscle and lipid accumulation. In diet-induced obese and insulin resistant mice, a diet with decreased levels of valine and the other branched-chain amino acids resulted in a rapid reversal of the adiposity and an improvement in glucose-level control. These effects pertain to 3-HIB and to valine itself, not to HIVA or to valine alpha-hydroxyisocaproate specifically, and they arise from animal models only.

6. Body Systems and Health Areas of Association

Skeletal muscle: The primary area of study for HICA and HIVA, encompassing protein synthesis, anti-catabolism, atrophy recovery, and exercise-induced soreness.
Connective tissue: HICA is described as an end product of leucine metabolism in human tissues such as muscle and connective tissue, and its MMP inhibitory activity is relevant to collagen and extracellular matrix integrity.
Hematopoietic system: Valine's essential role in hematopoietic stem cell maintenance is documented in animal models, though this relates to the intact amino acid.
Immune and inflammatory system: Early in vitro and pilot clinical data suggested anti-inflammatory or anti-catabolic activity, but these have not been confirmed in adequately powered human trials.
Antimicrobial/oral health: Emerging pre-clinical and ex vivo evidence for antibacterial activity.
Metabolic/insulin signaling: Limited to animal research on valine catabolites and their effect on lipid metabolism and insulin sensitivity.

7. Dosage Forms and Reported Dosages

No regulatory body (FDA, EFSA, or EMA) has established a recommended daily intake for HICA, HIVA, or valine alpha-hydroxyisocaproate as isolated compounds. The dosages described below reflect those reported in peer-reviewed research only.

HICA — human trial dosage: In the Karila et al. trial, subjects received 583 mg of the sodium salt of HICA (corresponding to 500 mg of HICA) mixed with liquid three times a day for 4 weeks, yielding a total daily dose of approximately 1,500 mg of HICA per day.
HICA — cited clinical dose: HICA supplementation of 1.5 g a day has been cited as the amount associated with small increases in muscle mass in the soccer player trial.
HICA — larger RCT: In the Teixeira et al. double-blind RCT evaluating off-the-shelf supplements, subjects received α-HICA (n = 10) with a fat-free mass of 62.0 ± 7.1 kg, alongside HMB-FA (n = 11) and HMB-Ca (n = 9) groups, with supplementation proceeding over 8 weeks of resistance training. Specific daily HICA dosage in this trial matched the product's label and was not found to differ from placebo on any outcome.
HICA — animal study: A rat study used a diet containing 5% α-hydroxyisocaproic acid; adult 14-week-old male Wistar rats were provided a control diet or an isonitrogenous isocaloric diet containing either 5% α-HICA or leucine.
HIVA — animal research: 2-Hydroxy-3-methylbutanoic acid is mainly used in animal nutrition research to evaluate its potential application as a nitrogen source substitute in feed. No established human dosage for HIVA has been reported in peer-reviewed clinical trials.

8. Safety Considerations and Interactions

8.1 Reported Safety in Human Studies

No changes in blood pressure, heart rate, or laboratory blood values were associated with the use of HICA in the soccer player study, suggesting that its use is safe within the 4-week, 1.5 g/day dosing regimen tested. No adverse events were reported in the Teixeira et al. (2019) trial across the 8-week supplementation period, consistent with HICA's status as an endogenous human metabolite found also in common fermented foods.

8.2 Nitrogen-Free Precursor Properties

In animal dietary experiments, when L-valine was replaced isonitrogenously by calcium L-alpha-hydroxyisovalerate, growth ceased and urea excretion increased. When L-leucine was replaced isonitrogenously by calcium L-alpha-hydroxyisocaproate, growth and feed efficiency fell approximately 60% and urea excretion rose. These findings, derived from weanling rat models in which the hydroxy acid was used as the sole nitrogen source for the relevant essential amino acid, indicate that alpha-hydroxy analogs are incomplete substitutes for their parent amino acids when consumed as the exclusive source of that amino acid's nitrogen contribution. They should not be used to replace dietary protein or individual essential amino acids.

8.3 Conflict of Interest and Reproducibility Concerns

The primary positive human trial for HICA carries a notable conflict of interest: the authors Dr. Tuomo Karila and Dr. Timo Seppälä are inventors of the HICA patent and are also partners at Oy Elmoped Ltd, the company commercializing the compound. Independent replication by the Teixeira group with a larger, better-powered cohort did not reproduce the beneficial effects on body composition, performance, or inflammation. This is a critical limitation when evaluating the totality of evidence.

8.4 Absence of Long-Term Safety Data

No long-term (beyond 8 weeks) human safety or efficacy data on supplemental HICA or HIVA have been published in peer-reviewed literature. No regulatory safety assessment by EFSA, the FDA, or comparable bodies has been published specifically for valine alpha-hydroxyisocaproate as a supplement ingredient.

8.5 Valine Metabolism and Systemic Metabolic Effects

Concerning the broader category of BCAA and valine metabolism, animal research has documented that alterations in circulating valine catabolite levels (particularly 3-hydroxyisobutyrate) can influence insulin sensitivity and lipid accumulation: the valine catabolite 3-hydroxyisobutyrate promotes insulin resistance in mice by stimulating fatty acid uptake into muscle and lipid accumulation. Whether supplemental valine alpha-hydroxyisocaproate, which is structurally distinct from 3-HIB, would exert similar metabolic effects has not been studied and cannot be assumed.

8.6 Potential for Interaction with BCAA Metabolism

As endogenous metabolites within the BCAA catabolic cascade, supplemental doses of HICA or HIVA may theoretically alter the equilibrium of branched-chain keto and hydroxy acid concentrations in plasma, potentially influencing the transamination balance of leucine, isoleucine, and valine. Studies measured plasma concentrations of the alpha-keto and alpha-hydroxy BCAA metabolites in normal volunteers after a protein meal or during a 60-h fast, and also determined the oxidoreduction equilibrium constants for HIVA/KIVA and HICA/KICA and their extent of plasma protein binding. The physiological significance of perturbing these equilibria with supplemental doses in healthy individuals is unknown.

Summary of Evidence

Valine alpha-hydroxyisocaproate, understood as encompassing the BCAA-derived alpha-hydroxy acid family (primarily HICA from leucine, and HIVA from valine), represents a category of endogenous human metabolites present in trace amounts in fermented foods. HICA has been the most intensively studied member in a human supplementation context. The early positive evidence from a small, industry-affiliated trial suggesting lean mass increases and reduced DOMS has not been reproduced by independent, larger, and more rigorous trials. The weight of available human evidence does not support HICA or related compounds as effective ergogenic aids for body composition or athletic performance. Antimicrobial properties have been demonstrated in pre-clinical and ex vivo settings but require human clinical investigation. Short-term safety at dosages of up to 1.5 g/day appears acceptable based on limited data, but long-term safety has not been characterized. Future studies are needed to compare the effects of different leucine metabolites, leucine itself, and leucine-rich food in humans.